Lawrence R
Schizophr Bull Open. 2024; 3(1):sgac058.
PMID: 39144771
PMC: 11205875.
DOI: 10.1093/schizbullopen/sgac058.
Kaur R, Sidana A, Malhotra N, Tyagi S
Indian J Psychiatry. 2023; 65(4):404-411.
PMID: 37325092
PMC: 10263095.
DOI: 10.4103/indianjpsychiatry.indianjpsychiatry_389_22.
Milz R, Benson C, Knight K, Antunes J, Najarian D, Lopez Rengel P
Neuropsychiatr Dis Treat. 2023; 19:531-545.
PMID: 36915909
PMC: 10008005.
DOI: 10.2147/NDT.S395383.
Lian L, Kim D, Procyshyn R, Cazares D, Honer W, Barr A
PLoS One. 2022; 17(4):e0267808.
PMID: 35486616
PMC: 9053823.
DOI: 10.1371/journal.pone.0267808.
Ceraso A, Lin J, Schneider-Thoma J, Siafis S, Tardy M, Komossa K
Cochrane Database Syst Rev. 2020; 8:CD008016.
PMID: 32840872
PMC: 9702459.
DOI: 10.1002/14651858.CD008016.pub3.
Maintenance antipsychotic treatment versus discontinuation strategies following remission from first episode psychosis: systematic review.
Thompson A, Winsper C, Marwaha S, Haynes J, Alvarez-Jimenez M, Hetrick S
BJPsych Open. 2018; 4(4):215-225.
PMID: 29988997
PMC: 6034451.
DOI: 10.1192/bjo.2018.17.
Fluphenazine (oral) versus placebo for schizophrenia.
Matar H, Almerie M, Sampson S
Cochrane Database Syst Rev. 2018; 6:CD006352.
PMID: 29893410
PMC: 6513420.
DOI: 10.1002/14651858.CD006352.pub3.
Fluphenazine decanoate (depot) and enanthate for schizophrenia.
Maayan N, Quraishi S, David A, Jayaswal A, Eisenbruch M, Rathbone J
Cochrane Database Syst Rev. 2015; (2):CD000307.
PMID: 25654768
PMC: 10388394.
DOI: 10.1002/14651858.CD000307.pub2.
The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal.
Brissos S, Ruiz Veguilla M, Taylor D, Balanza-Martinez V
Ther Adv Psychopharmacol. 2014; 4(5):198-219.
PMID: 25360245
PMC: 4212490.
DOI: 10.1177/2045125314540297.
Fluphenazine (oral) versus placebo for schizophrenia.
Matar H, Almerie M, Sampson S
Cochrane Database Syst Rev. 2013; (7):CD006352.
PMID: 23861067
PMC: 3997140.
DOI: 10.1002/14651858.CD006352.pub2.
Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials.
Kishimoto T, Robenzadeh A, Leucht C, Leucht S, Watanabe K, Mimura M
Schizophr Bull. 2012; 40(1):192-213.
PMID: 23256986
PMC: 3885289.
DOI: 10.1093/schbul/sbs150.
Oral versus Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Special Populations at Risk for Treatment Nonadherence: A Systematic Review.
Zhornitsky S, Stip E
Schizophr Res Treatment. 2012; 2012:407171.
PMID: 22966436
PMC: 3420751.
DOI: 10.1155/2012/407171.
The Potential Role of Long-acting Injectable Antipsychotics in People with Schizophrenia and Comorbid Substance Use.
Koola M, Wehring H, Kelly D
J Dual Diagn. 2012; 8(1):50-61.
PMID: 22754405
PMC: 3383636.
DOI: 10.1080/15504263.2012.647345.
Treatment of the special patient with schizophrenia.
Conley R, Kelly D
Dialogues Clin Neurosci. 2011; 3(2):123-35.
PMID: 22034474
PMC: 3181645.
Drug treatment of schizophrenia in the 1990s. Achievements and future possibilities in optimising outcomes.
Fleischhacker W, Hummer M
Drugs. 1997; 53(6):915-29.
PMID: 9179524
DOI: 10.2165/00003495-199753060-00002.
Will the new antipsychotics improve the treatment of schizophrenia?.
Hale T
BMJ. 1993; 307(6907):749-50.
PMID: 8106051
PMC: 1696416.
DOI: 10.1136/bmj.307.6907.749-a.
Long-term depot antipsychotics. A risk-benefit assessment.
Barnes T, Curson D
Drug Saf. 1994; 10(6):464-79.
PMID: 7917075
DOI: 10.2165/00002018-199410060-00005.
Depot antipsychotic drugs. Place in therapy.
Davis J, Matalon L, Watanabe M, Blake L, Metalon L corrected to Matalon L
Drugs. 1994; 47(5):741-73.
PMID: 7520856
DOI: 10.2165/00003495-199447050-00004.
Outcome and risks of ultra-long-term treatment with an oral neuroleptic drug. Relationship between perazine serum levels and clinical variables in schizophrenic outpatients.
Pietzcker A, Poppenberg A, Schley J, Muller-Oerlinghausen B
Arch Psychiatr Nervenkr (1970). 1981; 229(4):315-29.
PMID: 6111989
DOI: 10.1007/BF01833160.
Antipsychotic drugs in community-based sheltered-care homes.
Segal S, Chandler S, Aviram U
Soc Sci Med Med Psychol Med Sociol. 1980; 14A(6):589-96.
PMID: 6111128
PMC: 7434100.
DOI: 10.1016/0160-7979(80)90062-4.